News | Pharmaceuticals | October 04, 2017

MyoKardia Provides Update on MYK-491 Agent for Dilated Cardiomyopathy

Single ascending dose trial in healthy volunteers continues enrollment in order to refine exposure-activity-relationship; topline data expected by early 2018

October 4, 2017 — MyoKardia Inc. recently provided a clinical update on its MYK-491 program for dilated cardiomyopathy.

Earlier this year, MyoKardia initiated a Phase 1 single ascending dose trial of MYK-491 in healthy volunteers. The objectives of this randomized, placebo-controlled trial are to assess safety, tolerability, preliminary pharmacokinetics and pharmacodynamics of MYK-491.

Preliminary safety data available from this ongoing trial show that MYK-491 has been generally safe and well-tolerated in all dose cohorts tested thus far. Based on results observed to date, MyoKardia has elected to include additional dose cohorts in the trial in order to further refine its understanding of MYK-491 pharmacokinetics and pharmacodynamics. Topline data from the 001 trial are now expected to be released by early 2018.

MyoKardia intends to initiate a single ascending dose trial of MYK-491 in symptomatic DCM patients before year-end. The objectives of this randomized, double-blind, placebo-controlled trial are to assess safety, tolerability, preliminary pharmacokinetics and pharmacodynamics of MYK-491 in patients.

MYK-491 is an oral, small molecule, allosteric activator of myosin designed to increase cardiac contractility in a DCM heart. Reduced cardiac contractility, or hypocontractility, is believed to be the underlying cause of DCM and MYK-491 is designed to increase cardiac muscle contractility. Based on preclinical research across multiple animal models, MYK-491 may hold potential for controlled increases in the heart’s contractility with minimal impact on diastole or relaxation. MYK-491 is being studied in a Phase 1 single ascending dose trial in healthy volunteers.

For more information: www.myokardia.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now